» Articles » PMID: 35344339

Do Anti-tuberculosis Drugs Reach Their Target?─High-Resolution Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Provides Information on Drug Penetration into Necrotic Granulomas

Overview
Journal Anal Chem
Specialty Chemistry
Date 2022 Mar 28
PMID 35344339
Authors
Affiliations
Soon will be listed here.
Abstract

Tuberculosis (TB) is characterized by mycobacteria-harboring centrally necrotizing granulomas. The efficacy of anti-TB drugs depends on their ability to reach the bacteria in the center of these lesions. Therefore, we developed a mass spectrometry (MS) imaging workflow to evaluate drug penetration in tissue. We employed a specific mouse model that─in contrast to regular inbred mice─strongly resembles human TB pathology. was inactivated in lung sections of these mice by γ-irradiation using a protocol that was optimized to be compatible with high spatial resolution MS imaging. Different distributions in necrotic granulomas could be observed for the anti-TB drugs clofazimine, pyrazinamide, and rifampicin at a pixel size of 30 μm. Clofazimine, imaged here for the first time in necrotic granulomas of mice, showed higher intensities in the surrounding tissue than in necrotic granulomas, confirming data observed in TB patients. Using high spatial resolution drug and lipid imaging (5 μm pixel size) in combination with a newly developed data analysis tool, we found that clofazimine does penetrate to some extent into necrotic granulomas and accumulates in the macrophages inside the granulomas. These results demonstrate that our imaging platform improves the predictive power of preclinical animal models. Our workflow is currently being applied in preclinical studies for novel anti-TB drugs within the German Center for Infection Research (DZIF). It can also be extended to other applications in drug development and beyond. In particular, our data analysis approach can be used to investigate diffusion processes by MS imaging in general.

Citing Articles

The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.

Rompp A, Treu A, Kokesch-Himmelreich J, Marwitz F, Dreisbach J, Aboutara N Nat Commun. 2025; 16(1):826.

PMID: 39827265 PMC: 11742723. DOI: 10.1038/s41467-025-56146-9.


A Comparative Pharmacokinetics Study of Orally and Intranasally Administered 8-Nitro-1,3-benzothiazin-4-one (BTZ043) Amorphous Drug Nanoparticles.

Li F, Marwitz F, Rudolph D, Gauda W, Cohrs M, Neumann P ACS Pharmacol Transl Sci. 2024; 7(12):4123-4134.

PMID: 39698258 PMC: 11651166. DOI: 10.1021/acsptsci.4c00558.


Leveraging insights from cancer to improve tuberculosis therapy.

Datta M, Via L, Dartois V, Xu L, Barry 3rd C, Jain R Trends Mol Med. 2024; 31(1):11-20.

PMID: 39142973 PMC: 11717643. DOI: 10.1016/j.molmed.2024.07.011.


Multidrug-resistant tuberculosis.

Dheda K, Mirzayev F, Cirillo D, Udwadia Z, Dooley K, Chang K Nat Rev Dis Primers. 2024; 10(1):22.

PMID: 38523140 DOI: 10.1038/s41572-024-00504-2.


Mathematical model of oxygen, nutrient, and drug transport in tuberculosis granulomas.

Datta M, Kennedy M, Siri S, Via L, Baish J, Xu L PLoS Comput Biol. 2024; 20(2):e1011847.

PMID: 38335224 PMC: 10883541. DOI: 10.1371/journal.pcbi.1011847.